Beam Therapeutics (BEAM) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
12th Annual Cantor Fitzgerald Global Healthcare Conference summary
20 Sep, 2026Strategic portfolio and technology platform
Advancing a growing portfolio with commercial potential in gene editing for diseases like sickle cell, alpha-1 antitrypsin deficiency (AATD), PKU, and GSD1A.
Utilizing next-generation base editing (CRISPR 2.0) for precise single base changes without double-stranded breaks.
Demonstrated leadership and validation in base editing, with ongoing development in prime editing and targeted delivery technologies.
Fully integrated manufacturing and delivery capabilities, including internal cell and mRNA production, supporting rapid expansion to multiple indications.
Platform enables accelerated development cycles and operational efficiency across pipeline programs.
BEAM-302 for alpha-1 antitrypsin deficiency (AATD)
Targets a large unmet need by correcting the SERPINA1 gene mutation, converting the disease-causing Z allele to the normal M allele.
Demonstrated durable, one-time correction with patients achieving protective AAT levels and functional protein production.
Clinical data show normalization of AAT, elimination of toxic Z protein, and restoration of normal gene regulation.
Safety profile remains strong, with only transient, non-serious grade three liver enzyme elevation in a single patient.
Pivotal studies underway at 60 mg dose, with a significant lead over competitors and first-mover advantage in regulatory and commercial pathways.
Pipeline progress: PKU and risto-cel
BEAM-304 for PKU aims for a one-time cure by correcting point mutations, enabling normalization of phenylalanine metabolism and diet.
IND opened for BEAM-304, with innovative FDA platform approach allowing multiple editors and rapid expansion to other liver disorders.
Clinical trial for BEAM-304 expected to begin dosing by year-end or early next year, with quick escalation and expansion planned.
Risto-cel for sickle cell disease targets the sickest 10% of patients, offering best-in-class efficacy, rapid engraftment, and operational advantages.
All three programs (risto-cel, BEAM-302, BEAM-304) positioned as potential blockbuster franchises with sequential commercial launches.
Latest events from Beam Therapeutics
- BEAM-302 advances toward pivotal follow-up as risto-cel targets a December 2026 BLA.BEAM
Jefferies Global Healthcare Conference - Positive sickle cell results, advancing AAT enrollment and striking early GSD1a data drive the pipeline.BEAM
UBS Global Biopharma Conference 2026 - Risto-cel nears BLA filing as in vivo editing programs advance.BEAM
3rd Annual Guggenheim Healthcare Innovation Conference - Clinical programs advanced as Q3 losses widened and runway extended into mid-2029, subject to facility conditions.BEAM
Q3 2026 - Two of three patients at 40 mg reached 15-hour fasting and stopped starch supplementation.BEAM
Study result - Advancing curative gene therapies with strong financials and pivotal clinical milestones in 2026.BEAM
Corporate presentation - BEAM-302 gene editing achieved sustained, functional AAT restoration and was well tolerated.BEAM
European Respiratory Society Congress presentation - Advancing pivotal gene editing programs with strong data, regulatory momentum, and platform scalability.BEAM
Citigroup’s Biopharma Back to School Summit 2026 - Durable AAT restoration and >80% Z-AAT reduction advance toward pivotal approval.BEAM
Status update